What Are SGLT2 Inhibitors?
SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) are a class of oral diabetes medications that work by blocking glucose reabsorption in the kidneys. Unlike many other diabetes drugs that target insulin production or sensitivity, SGLT2 inhibitors cause excess glucose to be excreted through urine, effectively lowering blood sugar levels regardless of insulin function.
What makes SGLT2 inhibitors truly remarkable is their proven cardiovascular and kidney protective benefits — effects that go well beyond simple blood sugar control. This has made them one of the most prescribed diabetes drug classes worldwide.
Dapagliflozin (Forxiga): How It Works
Dapagliflozin is one of the most widely studied SGLT2 inhibitors. Marketed as Forxiga (AstraZeneca), it blocks SGLT2 proteins in the kidneys, preventing glucose from being reabsorbed into the bloodstream. The excess glucose is instead excreted in urine, providing several benefits:
- Lowers blood sugar: Reduces HbA1c by 0.5-1.0% on average
- Promotes weight loss: Patients typically lose 2-3 kg through calorie loss via glucosuria
- Reduces blood pressure: Mild diuretic effect lowers systolic BP by 3-5 mmHg
- Heart failure protection: Reduces hospitalization risk for heart failure by 30%
- Kidney protection: Slows progression of chronic kidney disease in diabetic patients
Dapagliflozin is available from 984 Online Pharmacy as Forxiga 10mg (98 tablets, 14×7 blister pack) from AstraZeneca India, plus the combination product Xigduo XR (Dapagliflozin + Metformin).
Empagliflozin: Key Differences
Empagliflozin (marketed as Jardiance) is another leading SGLT2 inhibitor with a similar mechanism of action. Key differences from Dapagliflozin include:
- Dosing: Empagliflozin is dosed at 10mg or 25mg once daily
- Cardiovascular data: The EMPA-REG OUTCOME trial showed a 38% reduction in cardiovascular death
- FDA approval: Empagliflozin has specific FDA approval for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
Both Dapagliflozin and Empagliflozin are considered first-line SGLT2 inhibitors with comparable efficacy and safety profiles. The choice between them often depends on specific patient factors, insurance coverage, and regional availability.
Benefits Beyond Blood Sugar: Heart and Kidney Protection
The most compelling reason to choose SGLT2 inhibitors is their proven benefits beyond glucose control:
- Heart failure reduction: Both Dapagliflozin and Empagliflozin reduce the risk of hospitalization for heart failure by 30-35%
- Kidney disease progression: SGLT2 inhibitors slow the decline of kidney function, reducing the risk of progression to end-stage renal disease by 40%
- Non-diabetic benefits: Recent studies show benefits in heart failure patients even without diabetes
- Mortality reduction: Significant reduction in all-cause mortality in patients with heart failure
Cost Comparison: Indian Generic SGLT2 Inhibitors
Indian branded options available through 984 Online Pharmacy offer substantial savings:
- Forxiga 10mg (98 tablets, AstraZeneca India): Approximately $70-$86 for a 3+ month supply
- Xigduo XR 10mg/1000mg (28 tablets, AstraZeneca): Approximately $38-$47
- Xigduo XR 10mg/500mg (28 tablets, AstraZeneca): Approximately $38-$47
- Brand-name Jardiance (USA, 30 tablets): Approximately $500-$600
- Brand-name Farxiga (USA, 30 tablets): Approximately $450-$550
Patients choosing Indian-sourced SGLT2 inhibitors can achieve 80-90% savings compared to Western pharmacy prices.
Side Effects and Precautions
SGLT2 inhibitors are generally well-tolerated, but patients should be aware of potential side effects:
- Urinary tract infections: Increased glucose in urine can promote bacterial growth
- Genital yeast infections: More common in women
- Dehydration: Mild diuretic effect may cause thirst or dizziness
- Ketoacidosis (rare): Can occur even with normal blood sugar levels
Frequently Asked Questions
Can I take SGLT2 inhibitors without metformin? Yes. SGLT2 inhibitors can be used as monotherapy or in combination.
Do SGLT2 inhibitors cause weight loss? Yes. Most patients experience modest weight loss of 2-4 kg.
Are SGLT2 inhibitors safe for the kidneys? Yes, they are kidney-protective. However, they should not be started if eGFR is below 30 mL/min.
Which is better: Dapagliflozin or Empagliflozin? Both are excellent choices with similar efficacy.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any diabetes medication. Prices are approximate ranges and subject to change.
SGLT2 inhibitors represent one of the most significant advances in diabetes management in the past decade. Originally developed as glucose-lowering agents, these medications have demonstrated remarkable cardiovascular and renal protective benefits that extend well beyond their effects on blood sugar. The EMPA-REG OUTCOME trial was the landmark study that first demonstrated these benefits, showing that empagliflozin reduced the risk of major adverse cardiovascular events by 14%, cardiovascular death by 38%, and hospitalization for heart failure by 35% in patients with type 2 diabetes and established cardiovascular disease.
Dapagliflozin, the other widely available SGLT2 inhibitor, has also shown impressive results. The DECLARE-TIMI 58 trial demonstrated a 17% reduction in cardiovascular death or hospitalization for heart failure, with particular benefit in patients with prior myocardial infarction. Dapagliflozin is also approved for heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status, based on the DAPA-HF trial, and for chronic kidney disease based on the DAPA-CKD trial. Empagliflozin similarly received FDA approval for heart failure with preserved ejection fraction (HFpEF) following the EMPEROR-Preserved trial results. These data suggest that SGLT2 inhibitors should be considered standard therapy for patients with type 2 diabetes and either established cardiovascular disease, heart failure, or chronic kidney disease.
Important safety considerations include an increased risk of genital mycotic infections, particularly in uncircumcised males and women, which can be managed with proper hygiene and over-the antifungal treatments. Euglycemic diabetic ketoacidosis is a rare but serious adverse effect that can occur even when blood glucose levels are normal, particularly during acute illness, surgery, or reduced caloric intake. Patients should be educated to temporarily discontinue SGLT2 inhibitors during periods of significant illness or before surgery. Generic versions of dapagliflozin and empagliflozin from Indian manufacturers are available at $15-30 per month, compared to $500-600 for the brand-name Farxiga and Jardiance in the US.
